Natera, Inc. – NASDAQ:NTRA
Founder-led company
Natera stock price today
$160.06
-0.19
-0.12%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Natera stock price monthly change
+43.60%
month
Natera stock price quarterly change
+43.60%
quarter
Natera stock price yearly change
+161.78%
year
Natera key metrics
Market Cap | 20.84B |
Enterprise value | 5.08B |
P/E | -9.75 |
EV/Sales | 6.20 |
EV/EBITDA | -9.85 |
Price/Sales | 6.23 |
Price/Book | 7.24 |
PEG ratio | 1.41 |
EPS | -3.13 |
Revenue | 1.20B |
EBITDA | -351.25M |
Income | -365.46M |
Revenue Q/Q | 52.11% |
Revenue Y/Y | 39.25% |
Profit margin | -66.79% |
Oper. margin | -65.96% |
Gross margin | 44.69% |
EBIT margin | -65.96% |
EBITDA margin | -29.06% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNatera stock price history
Natera stock forecast
Natera financial statements
Average Price Target
$148.43
Potential downside: -7.26%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 261.40M | -110.80M | -42.39% |
|---|---|---|---|
| Sep 2023 | 268.30M | -109.03M | -40.64% |
| Dec 2023 | 311.10M | -78.03M | -25.08% |
| Mar 2024 | 367.74M | -67.59M | -18.38% |
| Jun 2023 | 1247893000 | 651.74M | 52.23% |
|---|---|---|---|
| Sep 2023 | 1446520000 | 661.86M | 45.76% |
| Dec 2023 | 1457125000 | 691.79M | 47.48% |
| Mar 2024 | 1468205000 | 674.09M | 45.91% |
| Jun 2023 | -78.38M | 47.03M | 9.31M |
|---|---|---|---|
| Sep 2023 | -29.55M | 81.14M | 236.00M |
| Dec 2023 | -58.12M | 24.66M | 6.84M |
| Mar 2024 | 27.00M | 138.25M | 6.46M |
Natera alternative data
| Aug 2023 | 2,958 |
|---|---|
| Sep 2023 | 2,958 |
| Oct 2023 | 2,958 |
| Nov 2023 | 2,958 |
| Dec 2023 | 2,958 |
| Jan 2024 | 2,958 |
| Feb 2024 | 2,958 |
| Mar 2024 | 2,958 |
| Apr 2024 | 2,958 |
| May 2024 | 2,958 |
| Jun 2024 | 3,282 |
| Jul 2024 | 3,282 |
Natera other data
43.07%
-56.93%
of NTRA is owned by hedge funds
198
-77
42.38M
-65.52M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 57347 |
| Apr 2024 | 0 | 132206 |
| May 2024 | 0 | 41345 |
| Oct 2024 | 0 | 24071 |
| Nov 2024 | 0 | 99852 |
| Dec 2024 | 0 | 262895 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | FESKO JOHN officer: PRESIDENT, CHIEF BUS. .. | Common Stock | 1 | $157.95 | $158 | ||
Sale | FESKO JOHN officer: PRESIDENT, CHIEF BUS. .. | Common Stock | 668 | $159.6 | $106,615 | ||
Sale | MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA.. | Common Stock | 2 | $158.06 | $316 | ||
Sale | MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA.. | Common Stock | 3 | $158.19 | $475 | ||
Sale | MOSHKEVICH SOLOMON officer: PRESIDENT, CLINICALDIA.. | Common Stock | 2,423 | $159.6 | $386,720 | ||
Sale | SHEENA JONATHAN director, other: .. | Common Stock | 338 | $165.98 | $56,100 | ||
Sale | SHEENA JONATHAN director, other: .. | Common Stock | 1,825 | $167.25 | $305,231 | ||
Sale | SHEENA JONATHAN director, other: .. | Common Stock | 537 | $168.15 | $90,294 | ||
Sale | SHEENA JONATHAN director, other: .. | Common Stock | 152 | $166.01 | $25,233 | ||
Sale | SHEENA JONATHAN director, other: .. | Common Stock | 238 | $166.18 | $39,550 |
| Patent |
|---|
Grant Utility: Methods for preparing a DNA fraction from a biological sample for analyzing genotypes of cell-free DNA Filling date: 5 Oct 2021 Issue date: 20 Sep 2022 |
Grant Filling date: 21 Jun 2018 Issue date: 20 Sep 2022 |
Grant Filling date: 10 May 2016 Issue date: 20 Sep 2022 |
Application Filling date: 6 May 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 20 Mar 2019 Issue date: 16 Aug 2022 |
Application Filling date: 29 May 2020 Issue date: 11 Aug 2022 |
Grant Filling date: 28 Feb 2019 Issue date: 9 Aug 2022 |
Grant Filling date: 19 Jun 2018 Issue date: 9 Aug 2022 |
Grant Filling date: 24 Jan 2020 Issue date: 19 Jul 2022 |
Application Filling date: 11 Mar 2022 Issue date: 7 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Steve Leonard Chapman (1979) Chief Executive Officer, Pres & Director | $792,170 |
| Mr. Robert A. Schueren (1962) Chief Operating Officer | $691,170 |
| Mr. Michael Brophy (1980) Chief Financial Officer | $631,730 |
| Dr. Matthew Rabinowitz Ph.D. (1973) Co-Founder & Executive Chairman | $514,260 |
| Mr. Jonathan Sheena (1973) Co-Founder & Director | $293,910 |
GeneDx: Time To Buy The Dip
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
Natera: Poised For A Great Future But I'd Wait For A Pullback
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Showcasing Seeking Alpha's March 2024 New Analysts
Natera: Squeezing The Last Drop From NIPT Growth Engine
Natera: Cash Burn Remains A Concern
Natera Reexamined
-
What's the price of Natera stock today?
One share of Natera stock can currently be purchased for approximately $160.06.
-
When is Natera's next earnings date?
Unfortunately, Natera's (NTRA) next earnings date is currently unknown.
-
Does Natera pay dividends?
No, Natera does not pay dividends.
-
How much money does Natera make?
Natera has a market capitalization of 20.84B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.99% to 1.08B US dollars.
-
What is Natera's stock symbol?
Natera, Inc. is traded on the NASDAQ under the ticker symbol "NTRA".
-
What is Natera's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Natera?
Shares of Natera can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Natera's key executives?
Natera's management team includes the following people:
- Mr. Steve Leonard Chapman Chief Executive Officer, Pres & Director(age: 46, pay: $792,170)
- Mr. Robert A. Schueren Chief Operating Officer(age: 63, pay: $691,170)
- Mr. Michael Brophy Chief Financial Officer(age: 45, pay: $631,730)
- Dr. Matthew Rabinowitz Ph.D. Co-Founder & Executive Chairman(age: 52, pay: $514,260)
- Mr. Jonathan Sheena Co-Founder & Director(age: 52, pay: $293,910)
-
Is Natera founder-led company?
Yes, Natera is a company led by its founders Dr. Matthew Rabinowitz Ph.D. and Mr. Jonathan Sheena.
-
How many employees does Natera have?
As Jul 2024, Natera employs 3,282 workers, which is 11% more then previous quarter.
-
When Natera went public?
Natera, Inc. is publicly traded company for more then 10 years since IPO on 1 Jul 2015.
-
What is Natera's official website?
The official website for Natera is natera.com.
-
Where are Natera's headquarters?
Natera is headquartered at 13011 McCallen Pass Building A, San Carlos, CA.
-
How can i contact Natera?
Natera's mailing address is 13011 McCallen Pass Building A, San Carlos, CA and company can be reached via phone at +65 02499090.
-
What is Natera stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Natera in the last 12 months, the avarage price target is $148.43. The average price target represents a -7.26% change from the last price of $160.06.
Natera company profile:
Natera, Inc.
natera.comExchange:
NASDAQ
Full time employees:
3,282
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
13011 McCallen Pass Building A
San Carlos, CA 78753
San Carlos, CA 78753
CIK: 0001604821
ISIN: US6323071042
CUSIP: 632307104
